



All times are listed in Pacific Time (PT).

## **FRIDAY, MARCH 24, 2023**

1 RIDA 1, MARCH 24, 2023		
6:45 AM	Breakfast	
7:15 – 8:00 AM	Living With PBC: The Person Behind the Chart (Non-Accredited) Kris Kowdley, MD Sponsored by: Ipsen	
8:00 - 8:10 AM	Welcome	
8:10 – 8:40 AM	Health Disparities in NAFLD Keynote Speaker: Jeffrey Lazarus, PhD, MIH, MA	
	Session I: NASH Session Chair: Zobair Younossi, MD, MPH	
8:40 – 9:00 AM	Burden of Disease Jeffrey Lazarus, PhD, MIH, MA (Moderator) Kathleen Corey, MD, MPH, Scott Isaacs, MD, and Zobair Younossi, MD, MPH	
9:00 – 9:20 AM	NITS Laurent Castera, MD, PhD (Moderator) Alina Allen, MD, Mazen Noureddin, MD, MHSc, Jay Shubrook, DO, and Rohit Loomba, MD, MHSc	
9:20 – 9:40 AM	New Therapies in Development Stephen Harrison, MD (Moderator) Scott Friedman, MD, Jörn Schattenberg, MD, Shira Zelber-Sagi, PhD, and Christos Mantzoros, MD	
9:40 - 10:15 AM	Break/Visit Exhibits	
	Session II: Cholestatic Liver Disease & Autoimmune Liver Disease Session Chair: Kris Kowdley, MD	
10:15 – 10:25 AM	PBC: Therapeutic Advances in PBC (Real-World Cohort & Treatment) Raza Malik, MD, PhD	
10:25 – 10:35 AM	PBC Controversy: Are Treatment Goals Adequate? Should We Be Routinely Using Triple Combination Therapy? Raza Malik, MD, PhD, and Atoosa Rabiee, MD	
10:35 - 10:45 AM	PSC: Recent Advances in PSC Christopher Bowlus, MD	



10:45 - 11:00 AM	Use of Urso in PSC: Pro vs. Con Christopher Bowlus, MD (Pro), and Raza Malik, MD, PhD (Con)
11:00 – 11:15 AM	Autoimmune Hepatitis Controversy: Should Budesonide Be a First-Line Therapy for All Patients? Robert Fontana, MD (Pro), and Craig Lammert, MD (Con)
11:15 - 11:25 AM	Q&A Discussion
11:25 – 11:45 AM	<b>Developments in the Management of Alcohol Liver Disease</b> Steven Flamm, MD
11:45 AM - 12:00 PM	Lunch
12:00 – 12:45 PM	Albumin Use in Hepatorenal Syndrome (Non-Accredited) Kimberly Brown, MD Sponsored by: Mallinckrodt Pharmaceuticals
6:00 - 6:30 PM	Fellows and APP Networking Reception
6:30 - 8:30 PM	Conference Reception

## SATURDAY, MARCH 25, 2023

6:45 AM	Breakfast
7:15 – 8:00 AM	Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH): Impact, Identification, and Management (Non-Accredited) Steven Flamm, MD Sponsored by: Intercept Pharmaceuticals
8:00 - 8:10 AM	Welcome Back
	Session III: Hepatitis B & D Session Chair: Ira Jacobson, MD
8:10 - 8:30 AM	Case I: Management of HBV/HDV Coinfection Joseph Ahn, MD
8:30 - 8:50 AM	Case II: HBV: When Is It Okay to Stop Therapy? Paul Kwo, MD
8:50 - 9:10 AM	Case III: HBV: Management of Immunotolerant Patients Douglas Dieterich, MD
9:10 - 9:30 AM	Break/Visit Exhibits



9:30 – 10:00 AM	Elimination of Hepatitis C Keynote Speaker: John McHutchison, AO, MD
	Session IV: Controversies in the Management of Cirrhosis Session Co-Chairs: Marcelo Kugelmas, MD, and Sammy Saab, MD, MPH
10:00 – 10:30 AM	HRS: Positioning Treatments Todd Frederick, MD
10:30 - 11:00 AM	Baveno VII Criteria and Portal Hypertension Management David Bernstein, MD, and Nancy Reau, MD (Point-Counterpoint)
11:00 - 11:30 AM	The Role of Prophylactic Treatment in HE Robert Brown, MD, MPH (Con), and Mitchell Mah'moud, MD (Pro)
11:30 AM – 12:00 PM	Controversies on Albumin Use in Cirrhosis Hani Wadei, MD, and Nikolaos Pyrsopoulos, MD, PhD, MBA
12:00 - 12:15 PM	<b>Liver Connect Summary</b> Kimberly Brown, MD
12:15 - 12:30 PM	Lunch
12:30 – 1:15 PM	Emerging Concepts in Nonalcoholic Steatohepatitis (Non-Accredited) Kimberly Brown, MD, and Marcelo Kugelmas, MD Sponsored by: Madrigal Pharmaceuticals
2:00 - 6:10 PM	HBV/HDV-ACT   Advancing Curative Treatments - View CME Agenda Co-Chairs: Robert Gish, MD, and Ira Jacobson, MD

## **SUNDAY, MARCH 26, 2023**

6:45 AM Breakfast

6:10 - 8:00 PM

**HBV/HDV-ACT | Advancing Curative Treatments Continued** Co-Chairs: Robert Gish, MD, and Ira Jacobson, MD 7:00 - 10:00 AM

**HBV/HDV-ACT Reception**